Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $135.2857.
Several research firms have recently commented on BLLN. Piper Sandler reaffirmed an “overweight” rating on shares of Billiontoone in a research report on Wednesday, December 10th. Guggenheim assumed coverage on shares of Billiontoone in a report on Tuesday, January 6th. They issued a “buy” rating and a $120.00 target price for the company. Wells Fargo & Company assumed coverage on Billiontoone in a research report on Monday, December 1st. They set an “equal weight” rating and a $110.00 target price on the stock. Jefferies Financial Group started coverage on Billiontoone in a report on Monday, December 1st. They set a “hold” rating and a $117.00 price objective for the company. Finally, Wall Street Zen raised shares of Billiontoone to a “hold” rating in a research note on Saturday, November 15th.
Check Out Our Latest Report on Billiontoone
Institutional Trading of Billiontoone
Billiontoone Stock Performance
Shares of NASDAQ:BLLN opened at $88.61 on Friday. Billiontoone has a 1 year low of $80.00 and a 1 year high of $138.70. The company has a market capitalization of $4.06 billion and a P/E ratio of 886.10. The firm’s fifty day simple moving average is $90.47.
Billiontoone (NASDAQ:BLLN – Get Free Report) last posted its earnings results on Tuesday, December 9th. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.06). The business had revenue of $83.52 million for the quarter, compared to analyst estimates of $82.86 million.
About Billiontoone
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
Further Reading
- Five stocks we like better than Billiontoone
- ALERT: Drop these 5 stocks before January 2026!
- Buy This Stock Now
- Trump & Musk’s Secret Bet on Silver — Exposed
- Silicon Valley insiders hint at 12-month AI warning
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
